lsd1 inhibitor gsk2879552

Drug Overview

LSD1 inhibitor GSK2879552 is a highly specialized experimental cancer medicine. It belongs to a group of medicines known as epigenetic modifiers. It acts as a Targeted Therapy because it is designed to seek out and block a specific enzyme inside cancer cells that helps them grow and hide from the body’s natural defenses.

While it has shown promise in laboratory testing, it is still being heavily researched to understand exactly how safe and effective it is for human patients.

• Generic name: GSK2879552
• US Brand names: None (Currently an investigational drug)
• Drug Class: LSD1 inhibitor (Lysine-specific demethylase 1 inhibitor), Epigenetic Targeted Therapy
• Route of Administration: Oral (taken by mouth as a capsule)
• FDA Approval Status: Investigational. This medicine is not approved by the US Food and Drug Administration for general use and is only available through medical research studies.

What Is It and How Does It Work? (Mechanism of Action)

To understand how this Targeted Therapy works, we first have to look at how DNA is stored inside our cells. Our DNA is wrapped tightly around tiny protein spools called histones. The body uses chemical tags, like methyl groups, to tighten or loosen the DNA around these spools. This is known as epigenetics. By changing these tags, the cell can turn certain genes “on” or “off.”

Here is how the drug works at the molecular level:

Inside certain cancer cells, an enzyme called Lysine specific demethylase 1 (or LSD1) is too active. The job of LSD1 is to erase the methyl tags from a specific histone called histone H3 (specifically at the H3K4 position). When LSD1 erases these tags, it turns “off” the genes that normally tell a cell to mature, stop growing, and eventually die. Because these genes are turned off, the cancer cells stay immature and multiply out of control. This is a common problem in cancers like acute myeloid leukemia and small cell lung cancer.

When a patient takes GSK2879552, the medicine enters the cell and permanently glues itself to the LSD1 enzyme. By blocking LSD1, the drug stops the enzyme from erasing the methyl tags. The genes that control normal cell aging are suddenly turned back “on.” The cancer cells are forced to mature (a process called differentiation), which stops them from dividing. Eventually, this forced maturation triggers the cancer cells to die.

FDA-Approved Clinical Indications

Because this medicine is still experimental, it does not currently have any official FDA approved uses. However, it has been studied in clinical trials for the following conditions.

Oncological uses (Investigational):

• Relapsed or refractory acute myeloid leukemia (AML).
• High risk myelodysplastic syndromes (MDS).
• Small cell lung cancer (SCLC).
• Castration resistant prostate cancer (in early laboratory studies).

Non oncological uses:

• None at this time.

Dosage and Administration Protocols

Because it is an investigational medicine, the doses used in clinical trials were carefully adjusted by research doctors to find the safest amount.

Dose Adjustments:

If a patient develops severe drops in their blood counts (especially blood platelets), doctors will pause the medicine and lower the dose once the body recovers. Specific dose adjustments for kidney (renal) or liver (hepatic) insufficiency have not been fully established, but doctors monitor liver and kidney blood tests closely during trials to ensure the medicine is being cleared safely.

Clinical Efficacy and Research Results

Clinical research on GSK2879552 from 2020 to 2025 has provided cancer doctors with very important lessons.

In recent Phase 1 clinical trials for patients with acute myeloid leukemia and myelodysplastic syndromes, the drug was tested to see if it could force the blood cancer cells to mature. The results showed minor clinical responses in only about 5 percent of the patients. For example, a small number of patients saw their leukemia cells decrease significantly, but the medicine did not provide a large scale survival benefit across the entire group.

Because the medicine caused harsh side effects without shrinking the tumors enough, the drug maker decided to stop the main clinical trials for leukemia and small cell lung cancer early. The risk to the patients was considered greater than the benefit.

However, research did not stop there. Between 2023 and 2025, scientists began exploring how to use LSD1 inhibitors like GSK2879552 in combination with modern Immunotherapy. In laboratory models of small cell lung cancer, doctors found that blocking LSD1 makes the tumors more visible to the immune system. While it may not cure the cancer on its own, it acts as a primer, allowing immunotherapy drugs (like immune checkpoint inhibitors) to attack the cancer much more aggressively.

Safety Profile and Side Effects

Because this drug changes how genes are read in both cancer cells and healthy cells, it can cause significant side effects. The most severe effects involve the blood and the brain.

Common side effects (Occurring in greater than 10 percent of patients):

• Severe drop in blood platelets (thrombocytopenia), which causes easy bruising and bleeding.
• Decreased white blood cells with a fever (febrile neutropenia), which increases the risk of serious infections.
• Nausea and vomiting.
• Feeling extremely tired (fatigue).
• Low blood potassium levels (hypokalemia).

Serious adverse events:

• Severe bleeding events: Because platelets drop so low, patients are at a high risk for dangerous bleeding, including bleeding in the brain (subdural hemorrhage).
• Encephalopathy and cognitive disorders: Some patients in the trials developed severe confusion, memory problems, and delirium.

Black Box Warning:

Because this drug is investigational and not FDA approved, it does not carry an official Black Box Warning. However, clinical trial guidelines issue strong warnings to doctors regarding the high risk of severe bleeding and sudden changes in brain function.

Management strategies:

Doctors monitor patients with weekly blood tests. If blood platelets drop to dangerous levels, the patient will receive platelet transfusions to stop the bleeding, and the drug will be paused. To monitor for brain side effects, doctors perform regular memory and cognitive tests (like the Montreal Cognitive Assessment). If a patient shows sudden confusion, the medicine is stopped immediately.

Connection to Stem Cell and Regenerative Medicine (If Applicable)

Even though clinical trials for cancer were paused, GSK2879552 is currently making huge waves in the field of stem cell and regenerative medicine. Because the drug is so good at forcing cells to mature (differentiate), researchers are using it in laboratories to grow new human tissues.

In a major 2024 study, scientists used a cocktail of small molecules, including GSK2879552, on human pluripotent stem cells. They discovered that adding this drug drastically accelerated the growth of adult-like brain cells (neurons) in the lab. Normally, it takes months or years to grow mature human brain cells in a dish for research, but this epigenetic drug sped up the process significantly. This breakthrough is helping scientists build better models to study neurological diseases and test new regenerative stem cell therapies.

Patient Management and Practical Recommendations

Patient safety is the absolute priority when testing an investigational drug.

Pre-treatment tests to be performed:

• A complete blood count test to make sure red blood cells, white blood cells, and platelets are at safe levels before starting.
• A baseline cognitive and memory test to have a record of normal brain function.
• Comprehensive blood chemistry tests to check kidney, liver, and potassium levels.

Precautions during treatment:

• Patients are at a very high risk for bleeding. Activities that could cause injury, like contact sports or using sharp tools carelessly, must be avoided.
• The drug can cause extreme confusion, so patients should not drive or operate heavy machinery if they feel dizzy or foggy.

Do’s and Don’ts list:

• Do tell your doctor immediately if you experience severe headaches, sudden confusion, or changes in your vision, as these can be signs of bleeding or brain swelling.
• Do report any unusual bruising, bleeding from your gums, or dark colored stool.
• Do use a soft-bristle toothbrush and an electric razor to avoid accidental cuts.
• Do not take over-the-counter pain medicines like aspirin or ibuprofen without asking your doctor, as these thin the blood and increase bleeding risks.
• Do not start any new vitamin or herbal supplements without checking with your clinical trial team first.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and is not meant to replace professional medical advice, diagnosis, or treatment. GSK2879552 is an investigational drug, is not FDA approved for general use, and is only available through clinical trials. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition, clinical trial options, or cancer treatments. Do not disregard professional medical advice or delay seeking it because of something you have read in this material.